CDR3 Therapeutics

Executive Summary

CDR3 Therapeutics is a privately held, Cambridge-based biotechnology company focused on developing next-generation gene therapies for hematologic malignancies, specifically leukemia and lymphoma. Founded in 2019, the company addresses a critical limitation of current T-cell-based therapies: their short-lived effects in the body. CDR3’s proprietary platform aims to engineer durable, persistent T-cell responses by integrating novel gene-editing and cell engineering approaches, potentially enabling long-term disease control or cure. While the company remains in early preclinical stages, its differentiated strategy could overcome a key hurdle in adoptive cell therapy—persistence—and position it as a promising player in the competitive cell therapy landscape. The platform's ability to sustain antitumor activity may also reduce the need for repeated infusions, improving patient outcomes and treatment economics. However, given the early stage, significant technical and clinical risks remain, including proof-of-concept in humans, manufacturing scalability, and safety profile. CDR3 has not publicly disclosed specific pipeline candidates or funding rounds, but its innovative approach has attracted attention in the gene therapy community. The company’s success will depend on advancing its lead program to the clinic and demonstrating durable efficacy in early-phase trials. With no publicly available financial or operational milestones, CDR3 operates with limited visibility, underscoring the need for near-term catalysts to validate its technology.

Upcoming Catalysts (preview)

• Q3 2026IND/CTA Filing for Lead Program40% success
• Q4 2026Preclinical Data Presentation at Major Conference (e.g., ASH or SITC)60% success
• TBDSeries B or Strategic Partnership Announcement50% success